DB12055 (MK-0767 analog) is a covalent SARS-CoV-2 3CL protease inhibitor. DB12055 has the potential for the study of dyslipidemia and diabetes mellitus[1].
References
[1] Ronda K Rippley, et al. Human pharmacokinetics and interconversion of enantiomers of MK-0767, a dual PPARalpha/gamma agonist. J Clin Pharmacol. 2007 Mar;47(3):323-33. DOI:10.1177/0091270006297141 [2] Ying Wang, et al. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease. J Biomol Struct Dyn. 2023;41(24):15262-15285. DOI:10.1080/07391102.2023.2193994
